Opioid Use Disorder

Rapid Clinical Updates Society of Hospital Medicine

The OUD Endemic

Context: Over 2/3 of drug overdoses involve opioids. This is

> worse than it has ever been. Prevalence of heroin downtrending while rates of synthetic opioids (fentanyl) rising.¹


OUD results in multiple admissions and is estimated to cost >\$13B annually. Patients with OUD experience

longer LOS and worse outcomes.³ Hospitalization is a

"pivotal touch point" for these patients.²


Cutting Edge: SHM recommends all hospitalists obtain X-waivers and

appropriately prescribe naloxone.



Buprenorphine

Current:



Context:

Current:

Partial mu agonist that provides ceiling effect for opioid agonists. Inpatient initation of buprenorphien is dramatically better than opioid detoxification.⁴ Typically opioid free period is required. Once mild withdrawal is present (COWS ≥ 8), 2-8mg dose is started.

Max doses are 16mg on day 1, 24mg on day 2.

Cutting edge: Microdosing can avoid withdrawal symptoms and may be beneficial if regular use of fentanyl or long-acting opioids.

Methadone

Higher retention than buprenorphine but requires daily visits and is heavily regulated. Context:

Current: Peak effect is 3-4 hours but half-life is 24-36 hours so steady-state may not be achieved for 3-7 days.

Although methadone cannot be prescribed at discharge if being used for OUD, it still has utility for Cutting edge: intractable pain or other non-addiction indications.⁵ Typical starting dose is 10-30mg daily.

	Methadone	Buprenorphine
Retention	Higher than buprenorphine	Increased at doses >16mg
Office visits	Daily(dispensed directly to patients)	Daily to monthly
Inpatient prescribing	Any inpatient clinician during hospitalization	Any inpatient clinician during hospitalization
Discharge	Only via Opioid Treatment Program	Any provider with X-waiver
prescribing		
Sedation	Yes if high doses, non-tolerant patients, or slow	Minimal (ceiling effect for respiratory depression)
	metabolizers	
Initiation	Days-weeks to reach comfortable dose	Requires withdraw or microdosing

Acute/Perioperative Pain

Context: Therapies for treatment of OUD have historically been held during perioperative periods.

Current: Evidence is growing to suggest it is safe and effective to continue these medications throughout.⁶ Cutting Edge: Both buprenorphine and methadone can be split into BID or TID dosing for more effective analgesia and doses can be increased during hospitalization if needed for severe acute pain.⁷

References:

- CDC National Vital Statistics. Available at: https://www.cdc.gov/nchs/data/databriefs/db428.pdf
- LW Suen et al. National Prevalence of Alcohol and Other Substance Use Disorders Among Emergency Department Visits and Hospitalizations: NHAMCS 2014-2018. J GEN INTERN MED (2021). https://doi.org/10.1007/s11606-021-07069-w
- H Englander et al. Planning and Designing the Improving Addiction Care Team (IMPACT) for Hospitalized Adults with Substance Use Disorder. J Hosp Med. 2017;12(5):339-342.
- M Liebshutz et al. Buprenorphine Treatment for Hospitalized, Opioid-Dependent Patients: A Randomized Clinical Trial. JAMA Intern Med. 2014;174(8):1369-1376.
- DEA Publications. Available online at: www.DEAdiversion.usdoj.gov
- LA Haber et al. Things We Do for No Reason: Discontinuing Buprenorphine When Treating Acute Pain. J Josph Med. 2019;14(10):633-635.
- SAMHSA. Medications for Opioid Use Disorder For Healthcare and Addiction Professionals, Policymakers, Patients, and Families. Available online at: https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-002.pdf